Akero Therapeutics Inc (AKRO) Stock Price, Quote & News

Company Profile

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 487 6488

Website: akerotx.com

Address:

601 Gateway Boulevard, Suite 350, South San Francisco, United States

SannieVerraderlijk Aug. 20 at 1:38 PM

$AKRO added

0 · Reply

StockMktGuru Aug. 19 at 4:09 PM

$VKTX $ALT Yes, dude. You should, absolutely short $ALT, $MDGL, $TERN, $AKRO and go long $VKTX. You are a genius. Congratulations in advance. Thank you for your valuable suggestions. Just $120+ are you lowballing it?

0 · Reply

Thepatientone Aug. 19 at 12:30 PM

$ALT BIC - Sell your $AKRO, $MDGL, $VKTX, which now take a back stage to the superior Pemvi. Do you DD and invest wisely.

0 · Reply

Wolly99 Aug. 19 at 12:27 PM

$ALT eeeesshhhh....$VKTX data not great either. First $AKRO, now VKTX. $ALT looking better and better as the most comprehensive solution for obsity/MASH

2 · Reply

Theverypatientone Aug. 19 at 11:59 AM

$ALT BIC vs $AKRO, $MDGL, $VIK and all others. As stated before no other will be acquired before Altimmune.

1 · Reply

RNASequencing Aug. 18 at 2:20 AM

$AKRO will watch for dips tomorrow on knee jerk reaction to nvo approval

0 · Reply

NeverBearTrader2025 Aug. 17 at 11:01 PM

$AKRO Ahh. Very quiet here.

0 · Reply

DavidT305 Aug. 17 at 12:20 PM

$AKRO probably not so bad. Some fgf21s have better early data, Boston bio/ gsk

0 · Reply

Wolly99 Aug. 17 at 11:35 AM

$ALT oh man $AKRO missed on fibrosis stat sig (even had a small effect size of just 11% over PBO) in its 96 week final readout. Yikes! As an FGF21, you have one job: crush fibrosis. With the known bone porosity issues too, AKRO is dead IMO Maybe they can partner with ALT to save it

5 · Reply

SannieVerraderlijk Aug. 16 at 9:05 AM

$NVO $AKRO EFX/Wegovy combo incoming https://www.statnews.com/2023/06/05/akero-nash-ozempic-study/

1 · Reply

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

Aug 8, 2025, 7:15 AM EDT - 12 days ago

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 8, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Jun 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation

May 29, 2025, 10:05 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation

May 28, 2025, 7:00 AM EDT - 3 months ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 3 months ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect

May 21, 2025, 3:25 PM EDT - 3 months ago

Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments

May 18, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out

May 15, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect

May 13, 2025, 10:00 AM EDT - 3 months ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 12, 2025, 7:00 AM EDT - 3 months ago

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 11, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation

May 10, 2025, 10:00 AM EDT - 3 months ago

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

May 9, 2025, 7:41 AM EDT - 3 months ago

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

May 9, 2025, 7:11 AM EDT - 3 months ago

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

May 8, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation

May 7, 2025, 4:05 PM EDT - 3 months ago

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Apr 30, 2025, 7:00 AM EDT - 4 months ago

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Apr 29, 2025, 10:00 AM EDT - 4 months ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 6, 2025, 1:47 PM EDT - 4 months ago

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Feb 28, 2025, 7:00 AM EST - 6 months ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 4, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out

Jan 30, 2025, 4:05 PM EST - 7 months ago

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 28, 2025, 9:30 PM EST - 7 months ago

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jan 28, 2025, 2:38 PM EST - 7 months ago

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Jan 27, 2025, 4:01 PM EST - 7 months ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Jan 27, 2025, 12:10 PM EST - 7 months ago

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Jan 27, 2025, 11:30 AM EST - 7 months ago

Why did Akero (AKRO) stock soar 110% on Monday?

Jan 27, 2025, 9:01 AM EST - 7 months ago

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Jan 27, 2025, 6:52 AM EST - 7 months ago

Akero shares double after preliminary results from mid-stage trial for liver disease drug

Jan 27, 2025, 6:30 AM EST - 7 months ago

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Jan 24, 2025, 4:05 PM EST - 7 months ago

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Jan 24, 2025, 11:01 AM EST - 7 months ago

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Nov 15, 2024, 11:00 AM EST - 9 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Nov 13, 2024, 4:05 PM EST - 9 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 8, 2024, 7:00 AM EST - 10 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 21, 2024, 7:00 AM EDT - 10 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Sep 20, 2024, 3:37 PM EDT - 11 months ago

Akero Therapeutics: Good Candidate For The MASH Basket

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

SannieVerraderlijk Aug. 20 at 1:38 PM

$AKRO added

0 · Reply

StockMktGuru Aug. 19 at 4:09 PM

0 · Reply

Thepatientone Aug. 19 at 12:30 PM

$ALT BIC - Sell your $AKRO, $MDGL, $VKTX, which now take a back stage to the superior Pemvi. Do you DD and invest wisely.

0 · Reply

Wolly99 Aug. 19 at 12:27 PM

$ALT eeeesshhhh....$VKTX data not great either. First $AKRO, now VKTX. $ALT looking better and better as the most comprehensive solution for obsity/MASH

2 · Reply

Theverypatientone Aug. 19 at 11:59 AM

$ALT BIC vs $AKRO, $MDGL, $VIK and all others. As stated before no other will be acquired before Altimmune.

1 · Reply

RNASequencing Aug. 18 at 2:20 AM

$AKRO will watch for dips tomorrow on knee jerk reaction to nvo approval

0 · Reply

NeverBearTrader2025 Aug. 17 at 11:01 PM

$AKRO Ahh. Very quiet here.

0 · Reply

DavidT305 Aug. 17 at 12:20 PM

$AKRO probably not so bad. Some fgf21s have better early data, Boston bio/ gsk

0 · Reply

Wolly99 Aug. 17 at 11:35 AM

5 · Reply

SannieVerraderlijk Aug. 16 at 9:05 AM

$NVO $AKRO EFX/Wegovy combo incoming https://www.statnews.com/2023/06/05/akero-nash-ozempic-study/

1 · Reply

Wallst45 Aug. 15 at 3:15 PM

$AKRO is that why stock is dumping ?

0 · Reply

Whiskeyunderthebed Aug. 15 at 3:03 PM

$GALT $AKRO Akero Publishes 96-Week Phase 2b HARMONY Trial Results In The Lancet Showing Near Complete MASH Reversal In One-Third Of Patients On 50mg EFX

5 · Reply

Whiskeyunderthebed Aug. 15 at 3:01 PM

$MDGL $AKRO Akero Publishes 96-Week Phase 2b HARMONY Trial Results In The Lancet Showing Near Complete MASH Reversal In One-Third Of Patients On 50mg EFX

0 · Reply

Thestocktraderhubzee Aug. 15 at 9:38 AM

WATCHLIST AUG 15 2025 $LUNR Reuters Reports Intuitive Machines Submits Proposal For NASA's Lunar Terrain Vehicle Delivery And Operations Contract; NASA Is Expected To Announce The LTV Delivery And Demonstration Award By The End Of 2025 $AKRO Akero Publishes 96-Week Phase 2b HARMONY Trial Results In The Lancet Showing Near Complete MASH Reversal In One-Third Of Patients On 50mg EFX $LCID Lucid Unveils Gravity X Concept, A SUV Based On Gravity Grand Touring, Debuting Aug. 17 At Pebble Beach Concours $LIXT LIXTE Biotech Expects 2H 2025 Readouts From Phase 1B/2 Trials Of LB-100 In Ovarian Clear Cell Carcinoma, Soft Tissue Sarcoma, And MSS Colon Cancer $CLVT Clarivate Partners With University Of Melbourne To Implement Alma, Primo, Leganto, Rapido, And Open Workflows, Enhancing Library Systems And User Experience

0 · Reply

SannieVerraderlijk Aug. 15 at 8:33 AM

$AKRO Quiet here, thoughts on data anyone? 50mg looks good I'd say. Maintained response as well. Only thing is it doesn't look like a clear best in class compared to Tirzepatide. https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-announces-lancet-publication-phase-2b-harmony

2 · Reply

BiotechBonesaw Aug. 13 at 4:10 PM

$ALT $AKRO $VKTX $GPCR FYI Here’s an example of the bullshit you have to deal with some big pharma competitors. Want to read thru the details of this as some may be common practice (doctors are notoriously time limited so free timely education on new therapies is needed). $LLY & NVO’s scale makes it difficult to compete on a market access front but better therapies are on the way. https://stocktwits.com/news-articles/markets/equity/texas-sues-eli-lilly-over-bribery-allegations/chrxXhlRdJs

1 · Reply

Wallst45 Aug. 13 at 12:14 PM

$AKRO Insiders Selling: - https://www.investing.com/news/insider-trading-news/akero-therapeutics-director-henderson-sells-142k-in-shares-93CH-4187013

0 · Reply

Quantumup Aug. 13 at 11:49 AM

Piper Sandler y'day reiterated $MDGL Overweight/$400. & Jefferies (also A/O)⬆️ $MDGL PT to $502 from $411 and reiterated at a Buy. $IVA $AKRO $VKTX $ALGS ETNB SGMT NVO LLY #MASH Piper Sandler and Jefferies said:

0 · Reply

Wallst45 Aug. 13 at 10:29 AM

$AKRO Director reports Insider Selling

0 · Reply

Thepatientone Aug. 12 at 1:39 PM

$ALT BIC vs $AKRO, $ETNB, $MDGL $VIK. Do your DD and do not fall pray of MM manipulators..

1 · Reply

Wallst45 Aug. 11 at 4:04 PM

$AKRO why the dump ??

0 · Reply

SannieVerraderlijk Aug. 11 at 12:11 PM

$AKRO Will add on dips here, want to have a big position before this starts dominating the MASH space

0 · Reply

Market Cap	3.89B
Revenue (ttm)	0.00
Net Income (ttm)	-252.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.02

Volume	785,166
Avg Vol	1,299,912
Day's Range	N/A - N/A
Shares Out	79.99M
Stochastic %K	27%
Beta	-0.28
Analysts	Strong Sell
Price Target	$76.58